Pulmonary
Partner With Us
Advertisement
Conexiant chevron_right Pulmonary chevron_right New COVID Booster Matches Efficacy Raises Antibodies
From the Journals

New COVID Booster Matches Efficacy, Raises Antibodies

A phase 3 randomized trial found that Moderna’s next-generation COVID-19 vaccine, mRNA-1283, was non-inferior to the earlier mRNA-1273 vaccine in preventing COVID-19 and produced stronger neutralizing antibody responses.

Conexiant
Full Article Summary Notecard
  1. The trial enrolled 11,454 participants aged 12 and older.
  2. Vaccines tested: mRNA-1283.222 and mRNA-1273.222.
  3. Relative vaccine efficacy (rVE) of mRNA-1283 was 9.3% over mRNA-1273.
  4. rVE for severe COVID-19 was 38.1%.
  5. Neutralizing antibody concentrations favored mRNA-1283. 

Source: The Lancet Infectious Diseases

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.